BridgeMD
New treatment option for Recurrent Hepatocellular Carcinoma
Official title The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma
ClinicalTrials.gov ID: NCT06609850
What this study is testing
What is Lenvatinb?
Lenvatinb is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for recurrent hepatocellular carcinoma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Studies have shown that combination therapy of TACE with Lenvatinib could achieve better survival outcomes than TACE alone for hepatocellular carcinoma (HCC) at BCLC B stage. However, whether patients could benefit from the ablation for intermediate recurrent HCC (RHCC) is still need high quality clinical evidence.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- 18-75 years;
- RHCC diagnosed by imaging;
- intermediate-stage RHCC (two to three lesions which at least one was \>3 cm in size or more than three tumors);
- the tumor number was no more than six, and the maximum tumor diameter was ≤5 cm;
- absence of extrahepatic metastasis or macrovascular invasion;
You likely can't join if
- under 18 years or over 75 years of age;
- primary intermediate-stage HCC;
- RHCC with more than six tumors, or single RHCC (5) RHCC \>5cm; (6) extrahepatic metastasis; (7) macrovascular tumor thrombus;
See the full eligibility criteria
- 18-75 years;
- RHCC diagnosed by imaging;
- intermediate-stage RHCC (two to three lesions which at least one was \>3 cm in size or more than three tumors);
- the tumor number was no more than six, and the maximum tumor diameter was ≤5 cm;
- absence of extrahepatic metastasis or macrovascular invasion;
- Child-Pugh class A or B;
- TACE as initial treatment after tumor recurrence and showed no tumor progression after TACE.
- life expectance \>3 months;
- under 18 years or over 75 years of age;
- primary intermediate-stage HCC;
- RHCC with more than six tumors, or single RHCC (5) RHCC \>5cm; (6) extrahepatic metastasis; (7) macrovascular tumor thrombus;
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, None Selected, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, None Selected, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.